ZYNLONTA Market Summary

Key Factors Driving ZYNLONTA Growth

1. Potential expansion into earlier-line DLBCL is the largest near-term growth catalyst:

ZYNLONTA is currently approved in the U.S. for adults with relapsed/refractory large B-cell lymphoma after ≥2 systemic therapies. Its pivotal LOTIS-5 Phase III study evaluated ZYNLONTA plus rituximab in patients with relapsed/refractory DLBCL after ≥1 prior line. In June 2026, LOTIS-5 met its primary endpoint, showing a statistically significant improvement in PFS versus R-GemOx (HR 0.73; p=0.008), with median PFS of 6.1 vs. 4.7 months. ORR was 58.1% versus 45.2%, while CR was 39.5% versus 26.7%. ADC Therapeutics plans an sBLA submission in Q4 2026, creating the possibility of a broader second-line indication and a substantially larger eligible population.

2. Positive confirmatory data reduce a major commercial/regulatory uncertainty:

The positive LOTIS-5 result is particularly important because it provides confirmatory evidence for the ZYNLONTA + rituximab combination in a randomized Phase III setting. Median duration of response was 9.2 months vs. 7.7 months, and median duration of complete response was 16.8 vs. 12.3 months versus R-GemOx. Among patients achieving CR, 48.5% remained in CR at 24 months compared with 16.7% in the control arm. These data can support physician confidence and the company's planned regulatory expansion.

3. Combination with glofitamab could create another important treatment pathway:

LOTIS-7 is evaluating ZYNLONTA in combination with the CD20xCD3 bispecific antibody glofitamab (COLUMVI) in relapsed/refractory DLBCL. Updated Phase Ib results presented in December 2025 showed an 89.8% ORR and 77.6% CR rate among 49 efficacy-evaluable patients with at least six months of follow-up. Enrollment of approximately 100 patients was expected to be completed in H1 2026, with full data anticipated by the end of 2026. A successful development path could position ZYNLONTA in combination with an established bispecific rather than solely as monotherapy or with rituximab.

4. Potential expansion into follicular lymphoma provides a further revenue opportunity:

ZYNLONTA is being investigated in indolent B-cell lymphomas, including follicular lymphoma. In a Phase II investigator-initiated study of ZYNLONTA plus rituximab in relapsed/refractory FL, 67% of 39 patients achieved a complete response at week 12. The study population included clinically high-risk patients, including 51% with POD24 after first-line treatment. Although these results are from a small, single-arm study and do not establish an approved FL indication, they provide clinical evidence supporting continued development. ADC Therapeutics expected publication of its FL data as early as the end of 2026 and indicated that positive results could lead to regulatory/compendia strategies.

5. Durable responses in DLBCL support continued use of the existing product:

Long-term LOTIS-2 data demonstrated that ZYNLONTA can produce durable responses in heavily pretreated DLBCL. In the Phase II study, 48.3% of 145 patients achieved an overall response and 24.8% achieved CR. Among patients achieving CR, the median OS and PFS were not reached; estimated 24-month OS and PFS were 68.2% and 72.5%, respectively. Such durable responses are clinically relevant in later-line DLBCL, where treatment options remain limited.

ZYNLONTA Recent Developments

In June 2026, ADC Therapeutics announced topline results from its Phase III confirmatory trial evaluating ZYNLONTA in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The combination met its primary endpoint of statistically significant progression-free survival (PFS). However, the data also noted safety concerns, showing a higher rate of serious and Grade 5 adverse events compared to the control arm (primarily in patients aged 75 and older), which impacted the stock price.

“ZYNLONTA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ZYNLONTA for approved indication like Diffuse large B cell lymphoma; as well as potential indication like B-cell lymphoma, Follicular lymphoma, Marginal zone B-cell lymphoma, Waldenstrom’s macroglobulinaemia, and Mantle-cell lymphoma in the 7MM. A detailed picture of ZYNLONTA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ZYNLONTA for approved and potential indications. The ZYNLONTA market report provides insights about ZYNLONTA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZYNLONTA performance, future market assessments inclusive of the ZYNLONTA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZYNLONTA sales forecasts, along with factors driving its market.

ZYNLONTA Drug Summary

ZYNLONTA is a CD19-directed antibody–drug conjugate (ADC) developed by ADC Therapeutics for the treatment of adult patients with relapsed or refractory B-cell malignancies. The drug consists of a humanized monoclonal antibody targeting CD19, a protein expressed on the surface of B cells, conjugated to a potent DNA cross-linking pyrrolobenzodiazepine (PBD) dimer payload through a cleavable linker. Following intravenous administration, loncastuximab tesirine binds to CD19-expressing malignant B cells and is internalized, where the payload is released and causes DNA interstrand cross-links, disrupting DNA replication and transcription and ultimately inducing cancer-cell death. The report provides ZYNLONTA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ZYNLONTA Market Report

The report provides insights into:

• A comprehensive product overview including the ZYNLONTA MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma; as well as potential indication like B-cell lymphoma, Follicular lymphoma, Marginal zone B-cell lymphoma, Waldenstrom’s macroglobulinaemia, and Mantle-cell lymphoma.
• Elaborated details on ZYNLONTA regulatory milestones and other development activities have been provided in ZYNLONTA market report.
• The report also highlights ZYNLONTA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ZYNLONTA market report also covers the patents information, generic entry and impact on cost cut.
• The ZYNLONTA market report contains current and forecasted ZYNLONTA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ZYNLONTA market report also features the SWOT analysis with analyst views for ZYNLONTA in approved and potential indications.

Methodology

The ZYNLONTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYNLONTA Analytical Perspective by DelveInsight

• In-depth ZYNLONTA Market Assessment

This ZYNLONTA sales market forecast report provides a detailed market assessment of ZYNLONTA for approved indication like Diffuse large B cell lymphoma; as well as potential indication like B-cell lymphoma, Follicular lymphoma, Marginal zone B-cell lymphoma, Waldenstrom’s macroglobulinaemia, and Mantle-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZYNLONTA sales data uptil 2034.

• ZYNLONTA Clinical Assessment

The ZYNLONTA market report provides the clinical trials information of ZYNLONTA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ZYNLONTA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ZYNLONTA Market Potential & Revenue Forecast

• Projected market size for the ZYNLONTA and its key indications
• Estimated ZYNLONTA sales potential (ZYNLONTA peak sales forecasts)
• ZYNLONTA Pricing strategies and reimbursement landscape

ZYNLONTA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ZYNLONTA Market positioning compared to existing treatments
• ZYNLONTA Strengths & weaknesses relative to competitors

ZYNLONTA Regulatory & Commercial Milestones

• ZYNLONTA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ZYNLONTA Clinical Differentiation

• ZYNLONTA Efficacy & safety advantages over existing drugs
• ZYNLONTA Unique selling points

ZYNLONTA Market Report Highlights

• In the coming years, the ZYNLONTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ZYNLONTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNLONTA’s dominance.
• Other emerging products for Diffuse large B cell lymphoma; as well as potential indication like B-cell lymphoma, Follicular lymphoma, Marginal zone B-cell lymphoma, Waldenstrom’s macroglobulinaemia, and Mantle-cell lymphoma are expected to give tough market competition to ZYNLONTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNLONTA in approved and potential indications.
• Analyse ZYNLONTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ZYNLONTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZYNLONTA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ZYNLONTA? How strong is ZYNLONTA’s clinical and commercial performance?
• What is ZYNLONTA’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma; as well as potential indication like B-cell lymphoma, Follicular lymphoma, Marginal zone B-cell lymphoma, Waldenstrom’s macroglobulinaemia, and Mantle-cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNLONTA Manufacturers?
• What are the key designations that have been granted to ZYNLONTA for approved and potential indications? How are they going to impact ZYNLONTA’s penetration in various geographies?
• What is the current and forecasted ZYNLONTA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ZYNLONTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZYNLONTA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ZYNLONTA? What is the duration of therapy and what are the geographical variations in cost per patient?